Company Overview: RegeneRx Biopharmaceuticals

Industry News

8 Dec

RegeneRx Releases Annual Letter to Shareholders

ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ —RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter is focused on updating shareholders on the Company’s product development and commercial partnerships, clinical trials,...

Read more

16 Nov

Tβ4’s Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium

ROCKVILLE, Md., Nov. 16, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the...

Read more

31 Oct

RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial

ROCKVILLE, Md., Oct. 31, 2017 /PRNewswire/ –– RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the results of its phase 3 dry eye trial sponsored by its U.S. joint venture, ReGenTree, LLC.  The ARISE-2 trial investigated the...

Read more

13 Sep

RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.

ROCKVILLE, Md., Sept. 13, 2017 /PRNewswire/ –– RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Thymosin beta 4 (Tβ4) for use in the treatment...

Read more

31 Aug

RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia

Proceeds will Fund Operations Beyond Receipt of Phase 3 Dry Eye Trial Data ROCKVILLE, Md., Aug. 31, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a license expansion agreement with GtreeBNT for the...

Read more

14 Aug

RegeneRx Collaborators Receive Notice of ‘Intent to Grant’ EU Patent for the Treatment of Peripheral Neuropathy

Research Conducted Under Material Transfer Agreement Provides Potential Large Therapeutic Market Target for RGN-352 in the U.S. and EU ROCKVILLE, Md., Aug. 14, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent...

Read more

13 Jun

RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy

ROCKVILLE, Md., June 13, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that a Notice of Allowance has been received from the U.S. Patent and Trademark Office (USPTO) related to the composition and...

Read more

9 May

RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

ROCKVILLE, Md., May 9, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its joint venture, ReGenTree LLC, presented the results of its ARISE-1 Phase 2b/3 dry eye clinical trial in a poster session...

Read more

27 Feb

RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

ROCKVILLE, Md., Feb. 27, 2017 /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address